Explore Our Biomarker Menu

Biomarker:

M65 (Keratin18)

Biological or Clinical Significance:

The M65® ELISA measures soluble keratin 18 released from dying cells and can be used to assess total cell death due to apoptosis and necrosis. The assay is primarily intended to be used together with the M30 Apoptosense® ELISA, which specifically measures apoptosis. When used together, the quantification of total cell death, apoptosis and necrosis is possible. As both assays are calibrated against the identical reference, the combination of M30 Apoptosense® ELISA and M65® ELISA should allow determining the relative contribution of apoptosis to the total degree of cell death. M65® ELISA is intended for human sera, and is CE marked as a medical device for in vitro diagnostic use.

References:

Analyte:

M65 (Keratin18)

Matrix:

Human K2 EDTA Plasma

Status:

Validated

Sensitivity-LLOQ:

250 U/L

Sensitivity-ULOQ:

4,000 U/L

platform

ELISA

Required Sample Volume

25 µL/well

Disease State:

Oncology

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.